TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2013

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

Andre Goy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.